Structure Therapeutics Inc (GPCR)

Jan 6, 2025, 2:53 PM EST - 11 days ago

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

VKTX

Dec 17, 2024, 4:01 PM EST - 4 weeks ago

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Dec 5, 2024, 6:17 PM EST - 6 weeks ago

Structure CEO on the competitive landscape for oral GLP-1 drugs

NVO

Nov 15, 2024, 8:30 AM EST - 2 months ago

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 13, 2024, 4:01 PM EST - 2 months ago

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Oct 22, 2024, 2:07 PM EDT - 3 months ago

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Sep 17, 2024, 4:05 PM EDT - 4 months ago

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Aug 27, 2024, 4:05 PM EDT - 5 months ago

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Aug 26, 2024, 4:05 PM EDT - 5 months ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Aug 26, 2024, 12:00 PM EDT - 5 months ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP SRRK VKTX

Aug 23, 2024, 3:17 PM EDT - 5 months ago

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Jun 11, 2024, 6:37 PM EDT - 7 months ago

Structure Therapeutics CEO on GLP drugs

Jun 7, 2024, 4:05 PM EDT - 8 months ago

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Jun 5, 2024, 7:53 PM EDT - 8 months ago

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Jun 3, 2024, 6:27 PM EDT - 8 months ago

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Jun 3, 2024, 4:09 PM EDT - 8 months ago

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Jun 3, 2024, 2:38 PM EDT - 8 months ago

Structure Therapeutics reports promising weight-loss drug data

Jun 3, 2024, 8:42 AM EDT - 8 months ago

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Jun 3, 2024, 7:30 AM EDT - 8 months ago

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

May 7, 2024, 11:33 AM EDT - 9 months ago

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

AMGN LLY NVO ALT AZN VKTX

Apr 16, 2024, 7:09 PM EDT - 9 months ago

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

AMGN AZN LLY NVO PFE SNY VKTX

Mar 9, 2024, 2:30 AM EST - 11 months ago

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

NVO PFE VKTX

Mar 8, 2024, 4:05 PM EST - 11 months ago

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Mar 8, 2024, 8:30 AM EST - 11 months ago

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Jan 17, 2024, 3:40 PM EST - 1 year ago

The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

VKTX TERN

Dec 20, 2023, 11:17 AM EST - 1 year ago

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

LLY NVO ALT AMGN VKTX

Dec 18, 2023, 11:56 AM EST - 1 year ago

Structure Therapeutics reports promising results for weight-loss pill

Dec 18, 2023, 11:29 AM EST - 1 year ago

New Shakeup Hits Obesity Pills. Structure Rolls Out Disappointing Data.

Dec 18, 2023, 10:37 AM EST - 1 year ago

Structure's diabetes pill misses weight-loss expectations in mid-stage trial

Dec 18, 2023, 8:04 AM EST - 1 year ago

Structure Therapeutics stock plunges on new GLP-1 drug data

Dec 18, 2023, 7:30 AM EST - 1 year ago

Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

Nov 14, 2023, 4:10 PM EST - 1 year ago

Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Oct 3, 2023, 11:28 PM EDT - 1 year ago

Structure Therapeutics: Tipping The Scales In Obesity Management

Sep 29, 2023, 6:26 PM EDT - 1 year ago

Final Trades: Rivian, Pfizer, Treasury Bonds and more

PFE RIVN TLT

Sep 29, 2023, 12:02 PM EDT - 1 year ago

Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data

Sep 29, 2023, 10:15 AM EDT - 1 year ago

Structure Therapeutics surges on promising early stage obesity drug data

Sep 29, 2023, 8:02 AM EDT - 1 year ago

Structure Therapeutics shares surge after positive results in weight-loss trial, $300 million private placement

Sep 29, 2023, 7:32 AM EDT - 1 year ago

Structure Therapeutics Announces $300 Million Private Placement Equity Financing

Sep 29, 2023, 7:30 AM EDT - 1 year ago

Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update

Aug 10, 2023, 4:05 PM EDT - 1 year ago

Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

Aug 3, 2023, 5:32 PM EDT - 1 year ago

Structure Therapeutics Appoints Ted W. Love, M.D.

Jul 29, 2023, 6:15 AM EDT - 1 year ago

U.S. IPO Weekly Recap: July Closes Out With 2023's First Direct Listing And A Wave Of Small IPOs

ELWS FTEL INHD JNVR NRXS PRZO PXDT

Jun 7, 2023, 8:30 AM EDT - 1 year ago

Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions

May 31, 2023, 4:30 PM EDT - 1 year ago

Structure Therapeutics to Present at Jefferies Healthcare Conference

May 25, 2023, 4:30 PM EDT - 1 year ago

Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity

May 18, 2023, 4:30 PM EDT - 1 year ago

Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference

May 12, 2023, 7:28 AM EDT - 1 year ago

Weight-loss drug developers line up to tap market worth $150 billion

ALT AMGN AZN LLY MRK NVO PFE

May 11, 2023, 4:30 PM EDT - 1 year ago

Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

Apr 12, 2023, 4:31 PM EDT - 1 year ago

Structure Therapeutics: Developing Innovative Treatments For Metabolic And Fibrotic Diseases

Mar 30, 2023, 4:30 PM EDT - 1 year ago

Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights